Evidence map›Paper›PMID 33585224›Full record

ArticleFrontiers in oncology2020

Serum-Based KRAS

Ju Seok Kim, Go Eun Bae, Seok-Hwan Kim, Min Kyung Choi, Min-Kyung Yeo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Detection ofBiomolecules · 2021
    Trial
  2. Review
  3. Article
  4. Cancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ju Seok KimDepartment of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea.
Go Eun BaeDepartment of Pathology, Chungnam National University School of Medicine, Daejeon, South Korea.
Seok-Hwan KimDepartment of Surgery, Chungnam National University School of Medicine, Daejeon, South Korea.
Min Kyung ChoiDepartment of Pathology, Chungnam National University School of Medicine, Daejeon, South Korea.
Min-Kyung YeoDepartment of Pathology, Chungnam National University School of Medicine, Daejeon, South Korea.
Chungnam National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCell-free DNA (cfDNA) has arisen as an alternative target for evaluating somatic mutations in cancer. KRAS mutation status is critical for targeted therapy in colorectal adenocarcinoma (CRAC). We evaluated KRAS

methodsA total of 146 CRAC patients were enrolled, and KRAS

resultsDetection of KRAS

Indexed as

cell free DNAcolorectal adenocarcinomaheterogeneityKRASserum

Identifiers

PMID33585224
PMCPMC7873888
OpenAlexW3120478768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.